# Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Source: https://onco.cc/trials/nct07471789/  
OnCo record `nct07471789` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CART84 in acute myeloid leukaemia, run by Gyala Therapeutics, now recruiting.

## Summary

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). is a phase 1/2 interventional study registered as NCT07471789 by Gyala Therapeutics, with 33 participants planned, started 2026-02-04 and due to reach its primary completion in 2029-05-31. Interventions recorded: CART84.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07471789
- Phase: 1/2
- Setting: Phase I/IIa Clinical Trial With Dose Escalation to Evaluate Safety and Efficacy of the Infusion of CART84 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
- Sponsor: Gyala Therapeutics
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT07471789: https://clinicaltrials.gov/study/NCT07471789

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [CART84](https://onco.cc/drugs/cart84/)

---
JSON: https://onco.cc/api/v1/entities/nct07471789.json